See the DrugPatentWatch profile for Oxycontin
What were OxyContin’s peak annual sales?
OxyContin’s peak annual sales occurred in the mid-to-late 2000s, when the product generated roughly US$1 billion or more per year (sales later declined after major regulatory and legal scrutiny of Purdue Pharma and OxyContin marketing and prescribing).
When did OxyContin hit its highest revenue?
Public reporting and industry summaries commonly place OxyContin’s highest annual sales in the 2007–2010 window, after which growth slowed and sales began to fall. The decline is usually linked to stronger scrutiny, expanded prescribing controls, and shifting market access/usage patterns.
Why did OxyContin’s sales stop growing and then decline?
Reported drivers include:
- Increased legal and regulatory pressure on Purdue Pharma related to OxyContin promotion and prescribing practices.
- Changes in clinician and payer behavior as opioid prescribing policies tightened.
- Growing competition from other opioid formulations and the broader market shift away from long-acting oxycodone for many patients.
How to find the exact “peak annual sales” number you need
If you need the precise peak figure for a specific year (for example, “peak annual sales in 2008” vs “peak annual sales in the peak year”), it helps to specify:
- The year range you care about (calendar year vs fiscal year)
- Whether you mean “net sales” or “total sales” (companies and databases can label these differently)
- The geography (U.S.-only vs worldwide)
If you tell me which year (or which database/source style you’re using), I can help narrow the exact peak-sales figure to that format.